CORRESPONDENCE
TO THE EDITOR
We read with interest an updated analysis of TEL/AML1 incidence in relapsed ALL patients by Seeger et al. 1 Several reports have been published recently concerning the issue of prognostic impact of TEL/AML1. However, none of the major studies disputed better outcome of TEL/AML1-positive patients. [2] [3] [4] In this respect, disturbing phenomenon emerged in retrospective studies on relapsed ALL. Not only do the TEL/AML1-positive leukaemias relapse but in some studies their relapse rate appears to be unexpectedly high. 5 Prospective studies based on large cohorts of patients will contribute to disclosure of a real clinical significance of TEL/AML1 fusion gene. The major drawback of retrospective studies resides in a possible selection bias due to low availability of samples from a defined population. Present Seeger's data are based on testing 268 patients with relapsed B cell precursor (BCP) ALL while only 178 cases are included in the declared prospective study. Unfortunately, the proportion of evaluated samples is not mentioned. Moreover, only BCP ALL relapses are considered. In our opinion, exclusion of subgroups that are seemingly irrelevant for analysis (T lineage and mature B ALL) has no effect on the possible overall selection bias.
In our updated analysis (October 1994-April 1999) the incidence of TEL/AML1 among relapsed ALL patients is 12.1% (7/58), slightly higher than in our original report (8.9%, 4/45). 6 The incidence within BCP ALL increased from 11.8% (4/34) to 15.2% (7/46). However, in comparison to the incidence of TEL/AML1 positivity at diagnosis (59/241, 24.5%), the difference is statistically significant (12.1% vs 24.5%, P = 0.026). The significant level is reached even when we take into account only patients with BCP immunophenotype (15.2% (7/46) vs 29% (59/203), P = 0.037). Unfortunately, this kind of data is not provided by Seeger et al. Assuming a similar proportion of TEL/AML1-positive cases among newly diagnosed patients we can speculate that a comparable difference exists in the German population.
Among published studies, our cohort of relapsed patients is the most precisely defined and the possibility of bias is minimised. We are aware that the size of our cohort is markedly lower than that described by Seeger et al. Nevertheless, present updated analysis of TEL/AML1 incidence among Czech children with ALL at relapse is based on 58 patients. It is the second largest cohort published to date.
TEL/AML1-positive relapses are characterised by a long duration of first remission (11-89, median 34 months for positive vs 2-149, median 18 months for negative children; P = 0.016 in our study). We completely agree with Seeger et al that a long follow-up is necessary to establish the true relapse rate of TEL/AML1-positive ALL. Two studies with a long median follow-up (8.3 and 8.4 years) 2,3 documented highly significant differences in disease-free survival (DFS) between TEL/AML1-positive and negative patients (P = 0.004 and P Ͻ 0.001, respectively).
The incidence of TEL/AML1 among relapsed BCP ALL decreased from 22.5% 5 to 17.4% in Seeger's present study. This percentage (17.4%) is now very close to our updated result concerning children with BCP ALL (15.2%). Surprisingly, Dana-Farber Cancer Institute (DFCI) has reported strikingly better treatment results with no relapse in TEL/AML1-positive cohort (median follow-up 8.3 years). 3 Since the tendency to better in vitro sensitivity of TEL/AML1-positive cells to
